 CARLSBAD, Calif. , March 21, 2022 GLOBE NEWSWIRE -- Pardes Biosciences, Inc. NASDAQ: PRDS, a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases i.e., COVID-19, today announced that it will give an oral presentation at the 35th International Conference On Antiviral Research ICAR 2022, to be held in Seattle and virtually from March 21-25 2022. 